Shots: Intellia to receive $10M upfront, milestones and royalties on sales. Novartis to get rights to Intellia’s CRISPR/Cas9 technology for the development of ex-vivo cell therapy using ocular stem cells […]readmore
Tags : CRISPR/Cas9-Based Therapy